The Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine

Basit Öğe Kaydı
dc.contributor.authorArpaci, Nazile
dc.contributor.authorAk, Mehmet
dc.contributor.authorUguz, Faruk
dc.contributor.authorKurban, Sevil
dc.contributor.authorKulaksizoglu, Sevsen
dc.date.accessioned2024-02-23T14:41:15Z
dc.date.available2024-02-23T14:41:15Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjective: This study aimed to examine the role of central and peripheral neuropeptides in olanzapine-induced weight gain and metabolic changes. Materials and Methods: Thirty patients who would receive olanzapine treatment were evaluated at the beginning of the treatment at the 2nd and 8th weeks. Weight, waist circumference, the central neuropeptides pro-opiomelanocortin (POMC) and neuropeptide Y (NPY), and the peripheral adipokine leptin and the peripheral peptide cholecystokinin (CCK) levels were measured in each control. In addition, biochemical parameters such as fasting blood glucose (FBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total and direct bilirubin, very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, and triglyceride (TG) were measured. Results: There were statistically significant differences weight and waist circumference levels compared to the initial levels. As observed in previous studies in the literature, changes in biochemical parameters including AST, ALT, total and direct bilirubin, LDL, TG, total cholesterol, and HDL levels were statistically significant. Levels of the neuropeptides POMC and NPY tended to increase at early stages and decrease at later stages of the treatment, while CCK and leptin levels kept increasing throughout the treatment period. The changes in POMC and CCK levels were statistically significant. Conclusion: The results suggest that POMC and CCK may play a role in olanzapine-related weight gain.en_US
dc.identifier.doi10.5152/pcp.2021.20080
dc.identifier.endpage8en_US
dc.identifier.issn2475-0573
dc.identifier.issn2475-0581
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85129858876en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.5152/pcp.2021.20080
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16752
dc.identifier.volume31en_US
dc.identifier.wosWOS:000638999100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofPsychiatry And Clinical Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNeuropeptideen_US
dc.subjectOlanzapineen_US
dc.subjectWeight Gainen_US
dc.titleThe Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu